Добірка наукової літератури з теми "SERPINI1"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "SERPINI1".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "SERPINI1"
Mueller, S. K., A. L. Nocera, S. T. Dillon, T. A. Libermann, O. Wendler, and B. S. Bleier. "Tissue and Exosomal Serine Protease Inhibitors Are Significantly Overexpressed in Chronic Rhinosinusitis With Nasal Polyps." American Journal of Rhinology & Allergy 33, no. 4 (February 27, 2019): 359–68. http://dx.doi.org/10.1177/1945892419831108.
Повний текст джерелаHan, Sha, Fei Fei, Shaoyang Sun, Dongyang Zhang, Qiang Dong, Xu Wang, and Liang Wang. "Increased anxiety was found in serpini1 knockout zebrafish larval." Biochemical and Biophysical Research Communications 534 (January 2021): 1013–19. http://dx.doi.org/10.1016/j.bbrc.2020.10.048.
Повний текст джерелаBrzhozovskiy, Alexander G., Alexey S. Kononikhin, Lyudmila Ch Pastushkova, Daria N. Kashirina, Maria I. Indeykina, Igor A. Popov, Marc-Antoine Custaud, Irina M. Larina, and Evgeny N. Nikolaev. "The Effects of Spaceflight Factors on the Human Plasma Proteome, Including Both Real Space Missions and Ground-Based Experiments." International Journal of Molecular Sciences 20, no. 13 (June 29, 2019): 3194. http://dx.doi.org/10.3390/ijms20133194.
Повний текст джерелаMatsuda, Yasufumi, Koh Miura, Junko Yamane, Hiroshi Shima, Wataru Fujibuchi, Kazuyuki Ishida, Fumiyoshi Fujishima, et al. "SERPINI1 regulates epithelial–mesenchymal transition in an orthotopic implantation model of colorectal cancer." Cancer Science 107, no. 5 (March 28, 2016): 619–28. http://dx.doi.org/10.1111/cas.12909.
Повний текст джерелаCochran, Blake J., David R. Croucher, Sergei Lobov, Darren N. Saunders, and Marie Ranson. "Dependence on Endocytic Receptor Binding via a Minimal Binding Motif Underlies the Differential Prognostic Profiles of SerpinE1 and SerpinB2 in Cancer." Journal of Biological Chemistry 286, no. 27 (May 23, 2011): 24467–75. http://dx.doi.org/10.1074/jbc.m111.225706.
Повний текст джерелаWinkler, Ingrid G., Jean Hendy, Paul Coughlin, Anita Horvath, and Jean-Pierre Lévesque. "Serine protease inhibitors serpina1 and serpina3 are down-regulated in bone marrow during hematopoietic progenitor mobilization." Journal of Experimental Medicine 201, no. 7 (March 28, 2005): 1077–88. http://dx.doi.org/10.1084/jem.20042299.
Повний текст джерелаKara, Bülent, Cansu Eğilmez Sarıkaya, Yunus Emre Bayrak, Ayfer Sakarya Güneş, Mesut Güngör, and Gözde Yeşil. "Early-onset rapidly progressive myoclonic epilepsy associated with G392R likely pathogenic variant in SERPINI1." Seizure 80 (August 2020): 181–82. http://dx.doi.org/10.1016/j.seizure.2020.06.022.
Повний текст джерелаYamanaka, Sumitaka, Alexandru V. Olaru, Fangmei An, Delgermaa Luvsanjav, Zhe Jin, Rachana Agarwal, Ciprian Tomuleasa, et al. "MicroRNA-21 inhibits Serpini1, a gene with novel tumour suppressive effects in gastric cancer." Digestive and Liver Disease 44, no. 7 (July 2012): 589–96. http://dx.doi.org/10.1016/j.dld.2012.02.016.
Повний текст джерелаChen, Ping-Yen, Wun-Shaing W. Chang, Yiu-Kay Lai, and Cheng-Wen Wu. "c-Myc regulates the coordinated transcription of brain disease-related PDCD10–SERPINI1 bidirectional gene pair." Molecular and Cellular Neuroscience 42, no. 1 (August 2009): 23–32. http://dx.doi.org/10.1016/j.mcn.2009.05.001.
Повний текст джерелаTjärnlund-Wolf, A., S. Olsson, K. Jood, C. Blomstrand, and C. Jern. "No evidence for an association between genetic variation at the SERPINI1 locus and ischemic stroke." Journal of Neurology 258, no. 10 (April 13, 2011): 1885–87. http://dx.doi.org/10.1007/s00415-011-6022-0.
Повний текст джерелаДисертації з теми "SERPINI1"
Furtado, Clara Fernanda Barbirato. "Investigação de mutações nos genes LEPRE1, CRTAP, PPIB, FKBP10, SERPINH1 e SERPINF1 causadoras da osteogênese imperfeita recessiva." Universidade Federal do Espírito Santo, 2015. http://repositorio.ufes.br/handle/10/4522.
Повний текст джерелаA Osteogênese Imperfeita (OI) é uma doença clínica e geneticamente heterogênea caracterizada, predominantemente, por fragilidade e deformidade ósseas e por fraturas recorrentes. A maioria dos casos de OI resulta de mutações autossômicas dominantes nos genes COL1A1 e COL1A2, que codificam as cadeias formadoras do colágeno tipo I, principal proteína dos ossos. Nos últimos anos, um número crescente de casos decorrentes de mutações recessivas vem sendo relatado em genes associados à biossíntese do colágeno tipo I ou à formação e a mineralização óssea, como os genes LEPRE1, CRTAP, PPIB, FKBP10, SERPINH1 e SERPINF1. Mutações nesses genes, em geral, levam ao desenvolvimento de fenótipos graves e letais de OI. Neste trabalho, foram analisados os genes LEPRE1, CRTAP, PPIB, FKBP10, SERPINH1 e SERPINF1 de 25 pacientes com OI utilizando-se as técnicas de SSCP e sequenciamento. Ao todo, 29 variações genéticas foram detectadas, entre mutações e polimorfismos. Das onze variações encontradas no gene LEPRE1, estão a já bem descrita c.1080+1G>T e as mutações potencialmente deletérias c.2024G>A / p.Lys363Glu e c.1501C>T / p.Arg501Trp. No gene FKBP10, foi encontrada a também descrita duplicação c.831dupC, além da c.1546G>A / p.Leu516Phe, predita como causadora da doença. Observou-se que os genes FKBP10 e LEPRE1 contêm as principais mutações encontradas neste trabalho e sugere-se que os mesmos sejam preferencialmente analisados em estudos de triagem e identificação de mutações em OI. Até o momento, não existem relatos de mutações nos genes LEPRE1, CRTAP, PPIB, FKBP10, SERPINH1 e SERPINF1 em pacientes brasileiros e este trabalho fornece novas informações sobre os aspectos genéticos da OI recessiva
Osteogenesis Imperfecta (OI) is a clinically and genetically heterogeneous disease predominantly characterized by bone fragility and deformity and recurrent fractures. Most cases of OI result of autosomal dominant mutations in COL1A1 and COL1A2 genes that encode the chains forming type I collagen, the main protein in bones. In the past few years, an increasing number of cases due to recessive mutations has been reported in genes associated with the biosynthesis of type I collagen or to the formation and bone mineralization, such as LEPRE1, CRTAP, PPIB, FKBP10, SERPINH1 and SERPINF1. Mutations in these genes, in general, lead to the development of severe and lethal OI phenotypes. In this work, LEPRE1, CRTAP, PPIB, FKBP10, SERPINH1 and SERPINF1 of 25 OI patients were analyzed using SSCP and automated sequencing. Altogether, 29 genetic variations were detected, mutations and polymorphisms. Among the eleven variants found in LEPRE1 gene, there are the already well described c.1080 + 1G> T and the potentially deleterious mutations c.2024G> A / p.Lys363Glu and c.1501C> T / p.Arg501Trp . In FKBP10 gene, the previously described duplication c.831dupC, and c.1546G>A / p.Leu516Phe, predicted to be disease causing, were detected. It was observed that FKBP10 and LEPRE1 contain the most important mutations found in the patients studied in this work and it is suggested that LEPRE1 and FKBP10 should be preferably analyzed in studies of screening and identification of mutations in patients with OI. To date, there are no reports of mutations in LEPRE1, CRTAP, PPIB, FKBP10, SERPINH1 and SERPINF1 genes in Brazilian patients and this study provides new information on the genetic aspects of recessive OI.
Prévot, Pierre-Paul. "Rôles de la protéine Iris dans l'accomplissement du repas sanguin de la tique Ixodes ricinus." Doctoral thesis, Universite Libre de Bruxelles, 2007. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/210730.
Повний текст джерелаLa protéine Iris appartient à la famille des inhibiteurs de sérine protéases et présente une homologie significative avec l’inhibiteur d’élastase de leucocytes. Une analyse in silico a confirmé qu’Iris présentait la structure des serpines, et notamment le RCL (Reactive Center Loop), boucle responsable de l’activité anti-protéasique. Comme attendu (sur base de l’analyse in silico), Iris inhibe de manière spécifique l’activité de plusieurs sérine protéases, et en particulier l’élastase de leucocyte. Ces tests effectués, nous avons essayé de comprendre quel(s) pouvai(en)t être le(s) rôle(s) d’Iris dans l’accomplissement du repas sanguin de la tique, c’est à dire dans la lutte contre les différents systèmes de défenses de l’hôte.
Tout d’abord, des tests ont démontré la capacité d’Iris à inhiber les mécanismes de l’hémostase. Des tests sur du plasma et du sang complet ont montré qu’Iris allonge le temps de fibrinolyse, la voie intrinsèque de la coagulation et l’adhésion plaquettaire. L’utilisation de mutants a également démontré que si les deux premières activités sont dépendantes du RCL, et donc d’un mode de fonctionnement anti-protéolytique, l’adhésion plaquettaire est indépendante de ce système. Ce résultat met en évidence l’existence d’autres sites actifs, isolés par analyse in silico, nommés Receptor Binding Domain (RBD).
Un travail antérieur du laboratoire avait permis d’indiquer la capacité de la protéine recombinante Iris semi-purifiée à inhiber la production de TNF-a, d’IL-6, et d’IL-8 (cytokines pro-inflammatoires) ainsi que l’IFN-g par des PBMCs (Peripherical Blood Mononuclear Cells) humaines. Ces résultats ont été confirmés avec de la protéine purifiée. Des analyses complémentaires ont démontré qu’un mutant d’Iris - dépourvu d’activité anti-protéasique - conserve l’activité pro-inflammatoire. Là encore, ce mécanisme semble impliquer un ou plusieurs RBD. L’utilisation d’anticorps dirigés contre ces zones a permis de déterminer le domaine d’interaction (aa :105-120) impliqué dans cette fonction. D’autre part, une analyse par FACS a permis de démontrer qu’Iris interagit uniquement avec les cellules d’origine monocytaire.
Enfin, nous avons également analysé l’importance d’Iris au cours du repas sanguin de la tique par une approche vaccinale. Les résultats observés indiquent que 30 % des tiques nourries sur des lapins immunisés par la protéine rIris ne survivent pas au repas.
Doctorat en sciences, Spécialisation biologie moléculaire
info:eu-repo/semantics/nonPublished
Ulbricht, David, Jan Pippel, Stephan Schultz, René Meier, Norbert Sträter та John T. Heiker. "A unique serpin P1′ glutamate and a conserved β-sheet C arginine are key residues for activity, protease recognition and stability of serpinA12 (vaspin)". Portland Press, 2015. https://ul.qucosa.de/id/qucosa%3A33439.
Повний текст джерелаGötzfried, Jessica Tanja Tamara [Verfasser], and Karl-Peter [Akademischer Betreuer] Hopfner. "Genetic, biochemical and preclinical studies on a tandem cluster of two human serpins: alpha-1-antitrypsin and serpina2 / Jessica Tanja Tamara Götzfried ; Betreuer: Karl-Peter Hopfner." München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2018. http://d-nb.info/1160876223/34.
Повний текст джерелаMkaouar, Héla. "Rôle des serpines, inhibiteurs de protéases à serine, du microbiote digestif humain dans les maladies inflammatoires de l'intestin." Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS108.
Повний текст джерелаSerine protease inhibitors (Serpins) are a class of proteins that reamin poorly studied in bacteria. In this thesis we are interested in the study of serpins originating from the intestinal microbiota and the investigation of their anti-inflammatory potential for the treatment of inflammatory bowel diseases (IBD) in humans. For this we have identified serpins from the human gut microbiota and analyzed their diversity as well as their distribution between healthy and IBD patients. These data allowed isolating serpins significantly associated with IBD. The purification of four of them led us to demonstrate that they inhibit human proteases involved in IBD. Biochemical and kinetic analysis of these proteins showed that they exhibit original properties, in particular their high inhibition efficiency. The study of the protective effect of three serpins in an animal model of colitis demonstrated for the first time the efficacy of serpins in vivo demonstrating thus their therapeutic potential
Souza, Lucas Rodrigo de. "Desenvolvimento de bibliotecas baseadas em serpinas para geração de inibidores de calicreínas teciduais humanas." reponame:Repositório Institucional da UFABC, 2017.
Знайти повний текст джерелаTese (doutorado) - Universidade Federal do ABC, Programa de Pós-Graduação em Biossistemas, 2017.
As calicreinas teciduais humanas (KLKs) compreendem uma familia de quinze serino proteases encontradas em uma diversidade de fluidos e tecidos biologicos. Estas enzimas sao identificadas como possuindo papel em diferentes doencas como Alzheimer, cancer, dermatite atopica, esclerose multipla, Parkinson, psoriase e outras. Existe, portanto, uma crescente demanda por inibidores especificos para cada uma das calicreinas e este e o objetivo do nosso grupo de pesquisa na UFABC. Neste trabalho pretendemos gerar inibidores para as calicreinas teciduais humanas 3, 5 e 7, utilizando bibliotecas baseadas em duas serpinas diferentes: uma expressando a forma Pittsburgh do inibidor de proteinase-¿¿1 (IP-¿¿1 M358R), randomizada nos residuos 352-356 (P7-P3); e outra expressando a serpina bacteriana vioserpina, randomizada nos residuos 343-347 (P3-P2f). A abordagem do phage display foi eficaz para gerar as bibliotecas e o protocolo de bioselecao utilizado adequado para enriquecer diversas variantes reativas. Na selecao da biblioteca do IP-¿¿1 M358R, consensos PSEAL e PSRIL foram observados, para KLK5 e KLK7, respectivamente, e varias das sequencias selecionadas exibiram maiores taxas de inibicao para ambas as calicreinas, quando comparadas a molecula molde (IP-¿¿1 M358R). A variante HDVIL e o consenso PSRIL foram identificados como sendo altamente seletivos para a KLK7, com constantes de segunda ordem 14 e 33 vezes maiores que as para KLK5. Pudemos realizar uma selecao efetiva da biblioteca de vioserpina contra a KLK7, cujas variantes enriquecidos demonstraram uma preferencia geral pelo aminoacido Serina ocupando as posicoes P3, P1f, P2f e P1, seguido por uma Tirosina, tambem preferida em P2. A tecnica de phage display foi, portanto, eficiente como base para um estudo de especificidade, e para o desenvolvimento de melhores e mais especificos inibidores para as Calicreinas Teciduais Humanas, e pode ser utilizada para o desenvolvimento de novas bibliotecas, com outras regioes da RCL randomizadas, ou mesmo baseadas em outras serpinas.
The human tissue kallikreins (KLKs) comprise a family of fifteen serine proteases found in a diversity of biological fluids and tissues. These enzymes are identified as having a role in different diseases such as Alzheimer's, cancer, atopic dermatitis, multiple sclerosis, Parkinson's, psoriasis, and others. Thus there is a growing demand for specific inhibitors for each of these kallikreins, and this is the aim of our group at UFABC. In this work we intended to generate inhibitors for the human tissue kallikreins 3, 5 and 7, using libraries based on two different serpins: one expressing the Pittsburgh form of the human serpin á1-proteinase inhibitor (á1-PI M358R), randomized at residues 352-356 (P7-P3); and another one expressing the bacterial vioserpin, randomized at residues 343-347 (P3-P2¿). The phage display approach was effective to generate the libraries and the biopanning protocol used suitable to enrich numerous reactive variants. On the á1-PI M358R selection, loose consensus of PSEAL and PSRIL were observed, for KLK5 and KLK7, respectively, and several of the selected sequences exhibited higher inhibition rates when compared to the template molecule for both kallikreins. The variant HDVIL and consensus PSRIL were found to be highly selective for the KLK7, with second order constants 14- and 33-fold higher than the ones for KLK5. We could only perform an effective selection with the vioserpin library for the KLK7, whose enriched variants demonstrated a general preference for the amino acid Serine occupying the positions P3, P1¿, P2¿ and P1, followed by a Tyrosine, also preferred on the P2. The phage display approach was therefore effective as basis for a specificity study, and for the development of improved, more specific inhibitors for the Human Tissue Kallikreins, and can be used to develop new libraries, with other randomized RCL regions, or even based on other serpins.
Evans, Dyfed Ll. "The heparin activateable serpins." Thesis, University of Cambridge, 1991. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.385390.
Повний текст джерелаAymonnier, Karen. "La protease Nexine-1, une cible prometteuse dans le traitement de l'hémophilie et son rôle dans les polynucléaires neutrophiles." Thesis, Sorbonne Paris Cité, 2019. http://www.theses.fr/2019USPCC049.
Повний текст джерелаHemophilia is a disease caused by the lack of Factor VIII (FVIII), leading to insufficient thrombin production, and therefore bleeding. Recently, new therapeutic strategies for hemophilia treatment, that do not rely on clotting factor replacement, have emerged. We propose an innovative approach consisting in targeting a natural and potent thrombin inhibitor, expressed by platelets and called protease nexin-1 (PN-1). Our results demonstrated that blocking PN-1 increased, in vitro, thrombin generation in plasma from patients with hemophilia, and reduced blood loss in hemophiliac mice. Our study provides proof-of-concept that PN-1 neutralizing can be a a novel approach for future clinical care in hemophilia. The potential role of PN-1 in regulating inflammatory processes is not known. Vascular cells, platelets and inflammatory cells express PN-1, but no data are available concerning its expression and potential function in neutrophils. For the first time, we demonstrated the presence of PN-1 in neutrophils. Our data have shown that neutrophil recruitment was much less important in peritoneal cavity of PN-1-/- mice than in those of WT mice. These novel findings suggest that PN-1 is a serpin regulating positively PMNs functions
Pippel, Jan, E. Bartholomeus Kuettner, David Ulbricht, Jan Daberger, Stephan Schultz, John T. Heiker, and Norbert Sträter. "Crystal structure of cleaved vaspin (serpinA12)." De Gruyter, 2016. https://ul.qucosa.de/id/qucosa%3A33438.
Повний текст джерелаCrowther, Damian C. "The bioengineering of targeted serpins." Thesis, University of Cambridge, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.260598.
Повний текст джерелаКниги з теми "SERPINI1"
Lucas, Alexandra, ed. Serpins. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-8645-3.
Повний текст джерелаWhisstock, James C. Biology of serpins. Amsterdam [u.a.]: Elsevier, Acad. Press, 2011.
Знайти повний текст джерелаGeiger, Margarethe, Felix Wahlmüller, and Margareta Furtmüller, eds. The Serpin Family. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-22711-5.
Повний текст джерелаPotempa, Jan. Struktura, funkcja i ewolucja serpin. Kraków: Nakł. Uniwersytetu Jagiellońskiego, 1993.
Знайти повний текст джерелаGettins, Peter G. W. Serpins: Structure, function, and biology. Austin: R.G. Landes, 1996.
Знайти повний текст джерелаChurch, Frank C., Dennis D. Cunningham, David Ginsburg, Maureane Hoffman, Stuart R. Stone, and Douglas M. Tollefsen, eds. Chemistry and Biology of Serpins. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4615-5391-5.
Повний текст джерелаCarthy, Barry Mc. Ovalbumin, gene Y and serpin inhibitory function. Dublin: University College Dublin, 1998.
Знайти повний текст джерелаBarnes, Ruth C. Identification and characterisation of a novel human serpin gene: Leupin. Dublin: University College Dublin, 1998.
Знайти повний текст джерелаFestoff, Barry W., and Daniel Hantaï, eds. Serine Proteases and Their Serpin Inhibitors in the Nervous System. Boston, MA: Springer New York, 1990. http://dx.doi.org/10.1007/978-1-4684-8357-4.
Повний текст джерелаGeorgiev, Bojidor. Serpins and protein kinase inhibitors: Novel functions, structural features and molecular mechanisms. New York: Nova Science Publishers, 2010.
Знайти повний текст джерелаЧастини книг з теми "SERPINI1"
Czekay, Ralf-Peter, Tessa M. Simone, and Paul J. Higgins. "SerpinE1." In Encyclopedia of Signaling Molecules, 4902–13. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-67199-4_101828.
Повний текст джерелаCzekay, Ralf Peter, Tessa M. Simone, and Paul J. Higgins. "SerpinE1." In Encyclopedia of Signaling Molecules, 1–11. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4614-6438-9_101828-1.
Повний текст джерелаTravis, James. "Serpins." In Advances in Experimental Medicine and Biology, 1–4. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4615-5391-5_1.
Повний текст джерелаStone, Stuart R., James C. Whisstock, Stephen P. Bottomley, and Paul C. R. Hopkins. "Serpins." In Advances in Experimental Medicine and Biology, 5–15. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4615-5391-5_2.
Повний текст джерелаJohnson, Tierra A., Marguerite S. Buzza, Ekemini A. U. Riley, and Toni M. Antalis. "Plasminogen Activator Inhibitor Type-2 (PAI-2)/SerpinB2: A Unique Multifunctional Serpin." In The Serpin Family, 107–26. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-22711-5_8.
Повний текст джерелаMetze, Dieter, Tam Nguyen, Birgit Haack, Alexander K. C. Leung, Noriko Miyake, Naomichi Matsumoto, A. J. Larner, et al. "Deficiency of AT-III SERPINC1." In Encyclopedia of Molecular Mechanisms of Disease, 499. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-29676-8_6346.
Повний текст джерелаCierniewski, Czeslaw S., and Joanna Boncela. "Serpins in Angiogenesis." In Angiogenesis and Vascularisation, 101–18. Vienna: Springer Vienna, 2013. http://dx.doi.org/10.1007/978-3-7091-1428-5_5.
Повний текст джерелаCohen, Maja, Thomas H. Roberts, and Robert Fluhr. "Serpins in Plants." In The Serpin Family, 15–28. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-22711-5_2.
Повний текст джерелаPeng Loh, Y., Niamh Cawley, Alicja Woronowicz, and Josef Troger. "Serpinin Peptides: Tissue Distribution and Functions." In Chromogranins: from Cell Biology to Physiology and Biomedicine, 213–28. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-58338-9_13.
Повний текст джерелаAlberdi, Elena, and S. Patricia Becerra. "Inflammation and Noninhibitor Serpins." In Advances in Experimental Medicine and Biology, 307–39. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4615-5391-5_25.
Повний текст джерелаТези доповідей конференцій з теми "SERPINI1"
Pannekoek, H., M. Linders, J. Keijer, H. Veerman, H. Van Heerikhuizen, and D. J. Loskutoff. "THE STRUCTURE OF THE HUMAN ENDOTHELIAL PLASMINOGEN ACTIVATOR INHIBITOR (PAI-1) GENE: NON-RANDOM POSITIONING OF INTRONS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644767.
Повний текст джерелаNy, T., L. Hansson, and B. Åstedt. "ISOLATION OF cDNA FOR TYPE-2 PLASMINOGEN ACTIVATOR INHIBITOR." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642855.
Повний текст джерелаStrandberg, L., D. Lawrence, and T. Ny. "ISOLATION OF THE GENOMIC REGION CODING FOR TYPE-1 PLASMINOGEN ACTIVATOR INHIBITOR." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644439.
Повний текст джерелаLinja-Aho, Anna, Witold Mazur, Tuula Toljamo, Pentti Nieminen, Mikko Ronty, Steffen Ohlmeier, and Vuokko L. Kinnula. "Association Of SerpinA1 With Smoking And COPD." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a4362.
Повний текст джерелаNiemietz, C., S. Guttmann, V. Sandfort, and H. Schmidt. "SERPINA1 levels dictate TTR expression in HepG2 cells." In 35. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0038-1677092.
Повний текст джерелаNiemietz, C., and H. Schmidt. "Inverse Expression von SERPINA1 und TTR bei TTR Amyloidose." In Viszeralmedizin 2019. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1695237.
Повний текст джерелаFerrarotti, I., M. Zorzetto, I. Campo, S. Ottaviani, R. Scabini, M. Gorrini, and M. Luisetti. "SERPINA1 Gene Informative SNPs To Predict AAT Plasma Level." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a3504.
Повний текст джерелаOttaviani, Stefania, Anna Maria Fra, Alice Maria Balderacchi, Valentina Barzon, Tomas Patrick Carroll, Davide Piloni, Francesca Mariani, Noel Gerard Mc Elvaney, Angelo Guido Corsico, and Ilaria Ferrarotti. "Identification and characterisation of twenty-two novel SERPINA1 pathological mutations." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.4922.
Повний текст джерелаBarzon, Valentina, Alice Maria Balderacchi, Stefania Ottaviani, Angelo Giudo Corsico, and Ilaria Ferrarotti. "Rare SERPINA1 allele Mwhitstable in patients with Alpha1-antitrypsin deficiency." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa4060.
Повний текст джерелаVlasov, A. P., V. A. Trofimov, S. S. Al-Kubaysi, N. A. Myshkina, T. A. Muratova, L. N. Umnov, and M. Yu Khachaturov. "Personalized approach in optimizing the treatment of acute pancreatitis." In VIII Vserossijskaja konferencija s mezhdunarodnym uchastiem «Mediko-fiziologicheskie problemy jekologii cheloveka». Publishing center of Ulyanovsk State University, 2021. http://dx.doi.org/10.34014/mpphe.2021-60-62.
Повний текст джерела